Impact Factor
3.56
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.51
515 total citations
h5-index
32
h5 depth signal
Cited share
79.5%
124 of 156
Total citations
515
Citation footprint
Metric signal
3.37
External metric anchor
Self-citation
3.7%
19 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United Kingdom
255
United States
161
Australia
154
Canada
67
Germany
60
Citing Fields of Research
Healthcare Policy
329
Medical Ethics
324
Economics
120
Patient Care
68
Oncology
50
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
1,319
Articles tracked across the journal lifetime
Indexed publication set
156
124 cited publications
Last 12 months
67
5.6 publications/month
Open access share
62.7%
42 OA publications in the last year
Leading citing country
United Kingdom
255 citing publications
Leading citing field
Healthcare Policy
329 citing publications
Latest tracked publication
16 October 2026
10 recent records available
Coverage & Indexing History
v1n1, 2002-
v1n1, 2002-
Active Coverage
Research Focus & Classification
Indexed Subjects
Medical Ethics
Healthcare Policy
Broad Categories
Health Services
Public Health
Medical Ethics
MeSH Descriptors
Economics, Medical
Health Care Costs
Health Policy
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1007/s40258-026-01080-0
Open DOI
Cost Effectiveness of Sertraline for Preventing Domestic Violence Reoffending Among Highly Impulsive Violent Offenders in Australia: A Trial-Based Economic Evaluation
Background Domestic violence generates significant health and justice costs, yet there is little trial-based clinical or economic evidence on pharmacological interventions for high-risk offenders. We evaluated the cost effectiveness of s...
02
03
DOI 10.1007/s40258-026-01081-z
Open DOI
Cost-Effectiveness of Community Health Worker Interventions for Type 2 Diabetes Mellitus: A Systematic Review
04
05
DOI 10.1007/s40258-026-01078-8
Open DOI
Speed over Value: Korea’s Recent Overhaul in Pharmaceutical Pricing and Reimbursement
06
DOI 10.1007/s40258-026-01072-0
Open DOI
A Practical Framework for Understanding Cost-Effectiveness and Decision Risk in Health Benefits Package Design
07
08
09
DOI 10.1007/s40258-026-01064-0
Open DOI
Estimating the Share of Social Surplus Generated by Pharmaceutical Innovation Accruing to Manufacturers: A Systematic Literature Review
Introduction Pharmaceutical innovation operates within an implicit social contract that seeks to balance incentives for future drug development with equitable access to current therapies. A key metric for evaluating this balance is produ...
10
DOI 10.1007/s40258-026-01071-1
Open DOI
When Does Health Technology Assessment Need Deliberation? Evidence, Algorithms and the Limits of Consultation
Health technology assessment (HTA) increasingly depends on formal methods such as cost-effectiveness analysis, QALYs, thresholds, structured evidence reviews and decision criteria. These tools are indispensable, but they do not remove th...
Bibliographical & Catalog Notes
Title from cover.
Latest issue consulted: Vol. 1, no. 2 (2002).
No issues published for 2007.
Also issued online.